文献速递慢性肾脏病急性肾损伤

恩格列净对EMPA-KIDNEY研究中尿液生物标志物的影响

Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY.
PubMed 文献 · Am J Kidney Dis · 2025-10-31

本研究为EMPA-KIDNEY随机对照试验的二次分析,纳入2752例参与者,评估恩格列净10mg/日对比安慰剂对尿液肾小管和肾小球生物标志物的影响。结果显示恩格列净显著降低尿白蛋白19%、尿UMOD 63%,升高A1M 29%、DKK-3 22%、NGAL 7%,对EGF、KIM-1、MCP-1无显著影响。探索性中介分析提示白蛋白尿和UMOD的降低解释了恩格列净对eGFR斜率有益效应的32%。

要点

  • 恩格列净大幅且持续降低尿UMOD达63%,独立于基线糖尿病状态、肾病病因及eGFR/白蛋白尿水平。
  • 恩格列净降低尿白蛋白19%、总蛋白7%,升高部分近端小管重吸收标志物,但不一致影响小管损伤标志物。
  • 白蛋白尿和UMOD降低可能部分介导恩格列净的肾脏保护作用,但需实验验证因果关系。

核心结论

  • SGLT2抑制大幅且持续降低尿UMOD,并升高部分近端小管重吸收标志物,但不一致影响小管损伤标志物。

研究设计与样本

  • EMPA-KIDNEY随机对照试验的二次分析,纳入2752例参与者,比较恩格列净10mg/日与安慰剂。
  • 尿液生物标志物经尿肌酐校正,并在研究期间各时间点取平均值,采用混合模型重复测量分析。

主要发现

  • 恩格列净降低尿白蛋白19%(95%CI -24%至-14%)、总蛋白7%(-11%至-2%)、UMOD 63%(-65%至-61%)。
  • 恩格列净升高A1M 29%(25%至34%)、DKK-3 22%(16%至29%)、NGAL 7%(0至13%)。
  • 对EGF 1%(-1%至4%)、KIM-1 2%(-1%至6%)、MCP-1 0(-4%至3%)无显著影响。
  • 生物标志物效应在随访2个月和18个月时 generally 相似,UMOD大幅降低独立于基线糖尿病状态、肾病病因及eGFR/白蛋白尿水平。
  • 探索性中介分析提示白蛋白尿和UMOD降低解释了恩格列净对慢性eGFR斜率有益效应的32%(15%至52%)。

关键数值与推荐

  • 尿白蛋白降低19%(95%CI -24%至-14%),总蛋白降低7%(-11%至-2%),UMOD降低63%(-65%至-61%)。
  • A1M升高29%(25%至34%),DKK-3升高22%(16%至29%),NGAL升高7%(0至13%)。
  • EGF变化1%(-1%至4%),KIM-1变化2%(-1%至6%),MCP-1变化0(-4%至3%),均无统计学显著性。
  • 中介分析中白蛋白尿和UMOD降低介导32%(15%至52%)的eGFR斜率获益。

临床怎么用

  • 恩格列净对尿UMOD的大幅降低提示髓袢升支粗段可能是SGLT2抑制剂肾脏保护的新机制靶点。
  • 临床解读恩格列净治疗患者的尿液生物标志物时,需考虑UMOD降低和近端小管重吸收标志物升高的预期效应。
  • 尿白蛋白和UMOD的降低可能有助于监测恩格列净的肾脏保护作用,但尚不能作为因果替代指标。

局限性

  • 中介分析不能正式确认UMOD降低是SGLT2抑制剂肾脏获益的因果中介。
  • 研究为EMPA-KIDNEY试验的二次分析,生物标志物结果需进一步实验探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Sodium/glucose cotransporter 2 (SGLT2) inhibitors substantially slow progression of chronic kidney disease and reduce the risk of acute kidney injury, but their effects on kidney physiology are incompletely understood. This study assessed the effects of empagliflozin on a comprehensive set of urinary tubular and glomerular biomarkers. STUDY DESIGN: Randomized controlled trial. SETTING & PARTICIPANTS: 2,752 participants from EMPA-KIDNEY. EXPOSURE: Empagliflozin, 10 mg daily, versus placebo. OUTCOME: Urine biomarkers indexed to urinary creatinine and averaged across on-study time points. Urine biomarkers included markers of glomerular disease (albumin, total protein); proximal tubular reabsorption (α1-microglobulin [A1M]); functional tubular reserve (epidermal growth factor [EGF], uromodulin [UMOD]); tubular injury/inflammation (kidney injury molecule-1 [KIM-1], neutrophil gelatinase-associated lipocalin [NGAL]); and tubular ischemia/stress (dickkopf-3 [DKK-3], monocyte chemoattractant protein-1 [MCP-1]). ANALYTICAL APPROACH: Mixed model repeated measures. RESULTS: Allocation to empagliflozin reduced urinary albumin by 19% (95% CI, -24% to -14%), total protein by 7% (-11% to -2%), and UMOD by 63% (-65% to -61%). It increased A1M by 29% (25%-34%), DKK-3 by 22% (16%-29%), and NGAL by 7% (0-13%). Overall, there were no significant effects on EGF (1% [-1% to 4%]), KIM-1 (2% [-1% to 6%]), and MCP-1 (0 [-4% to 3%]). The magnitude of effects on biomarker levels was generally similar at 2 and 18 months of follow-up. The large reductions in UMOD were evident regardless of baseline diabetes status, primary cause of kidney disease, and level of estimated glomerular filtration rate (eGFR) and/or albuminuria. Exploratory mediation analyses suggest that reductions in albuminuria and UMOD accounted for 32% (15% to 52%) of the beneficial effect of empagliflozin on chronic eGFR slope. LIMITATIONS: The mediation analyses cannot be used to formally confirm that UMOD reduction is a causal mediator for the kidney benefits of SGLT2 inhibitors. CONCLUSIONS: SGLT2 inhibition imparts a large and sustained reduction in urinary UMOD and also increases some biomarkers partially reabsorbed by proximal tubules without consistently affecting markers of tubular injury. These effects deserve further detailed experimental exploration, particularly the effect on thick ascending limb-derived UMOD, which could represent a novel mechanism of kidney protection. PLAIN-LANGUAGE SUMMARY: Sodium/glucose cotransporter 2 inhibitors or "flozins" are medications that prevent kidney failure and acute kidney injury in a broad range of patients with kidney disease. However, exactly how these drugs exert their kidney protective effects is incompletely understood. In a large clinical trial involving patients with varying causes of kidney disease, empagliflozin reduced excretion of 2 common proteins in the urine (albumin and uromodulin). The substantial reduction in uromodulin was unexpected and is of particular interest because uromodulin is manufactured in a later part of the kidney beyond the site of action of empagliflozin. New experiments are needed to understand these results and assess whether the effect on uromodulin can explain the benefits of flozins for the kidney.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Malijan GB, Sardell RJ, Staplin N, et al. Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY. Am J Kidney Dis. 2025. PMID: 41177216. doi:10.1053/j.ajkd.2025.10.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。